Europe PMC / Molecular Genetics and Metabolism · Jul 2024
Preclinical study reported NtBuHA reduced AFSM accumulation, neuroinflammation, seizure burden, and improved motor function in Cln1-/- mice.
Utilizing monogenic disorders to inform and solve highly complex…
Company research
Public company, workplace, funding, and market signals
Overview
Circumvent Pharmaceuticals is a Portland-based biotech developing precision medicines for neurodegenerative disease, with an initial focus on CLN1 Batten disease. Its lead program centers on NtBuHA/CIRC825, a small-molecule PPT1/thioesterase mimetic intended to modulate protein palmitoylation and support oral treatment for rare pediatric neurodegeneration.
Primary product
NtBuHA (CIRC825), an oral small-molecule PPT1/thioesterase mimetic for CLN1 Batten disease
Founded
2017
Headquarters
Portland, Oregon, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Rare disease / neurodegenerative therapeutics
Offices
4640 SW Macadam Avenue Suite 200, Portland, OR 97239
Open Positions
0 jobs at Circumvent
No open positions
Check back later for new openings